Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Toxicology
Published in: Cardiovascular Toxicology 2/2022

01-02-2022 | Interferon

Curcumin Ameliorates Doxorubicin-Induced Cardiotoxicity and Hepatotoxicity Via Suppressing Oxidative Stress and Modulating iNOS, NF-κB, and TNF-α in Rats

Authors: Ghadha Ibrahim Fouad, Kawkab A. Ahmed

Published in: Cardiovascular Toxicology | Issue 2/2022

Login to get access

Abstract

Doxorubicin (DOX) is one of the widely used anti-tumor drugs. However, DOX-induced cardiotoxicity (DIC) and hepatotoxicity (DIH) are among the side effects that limited its therapeutic efficiency and clinical applicability. This study aimed to investigate the cardioprotective and hepatoprotective potentials of curcumin (CMN)—a bioactive polyphenolic compound—in alleviating DOX-induced cardiotoxicity (DIC) and hepatotoxicity (DIH) in male rats. A single intraperitoneal (i.p.) dose of DOX (20 mg/kg) was used to induce DIC and DIH. DOX-intoxicated rats were co-treated with CMN (100 mg/kg, oral) for 10 days before and 5 days after a single dose of DOX. We studied the anti-inflammatory and anti-oxidative activities of CMN on biochemical and immunohistochemical aspects. DOX disrupted cardiac and hepatic functions and stimulated oxidative stress and inflammation in both tissues that was confirmed biochemically and immunohistochemically. DOX enhanced inflammatory interferon-gamma (IFN-γ) and upregulated immunoexpression of nuclear factor-κB (NF-κB), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-alpha (TNF-α). DOX induced structural alterations in both cardiac and hepatic tissues. CMN demonstrated cardioprotective potential through reducing cardiac troponin I (cTn1) and aspartate amino transaminase (AST). In addition, CMN significantly ameliorated liver function through decreasing alanine amino transaminase (ALT) and, gamma-glutamyl transferase (GGT), total cholesterol (TC), and triglycerides (TG). CMN demonstrated anti-inflammatory potential through decreasing IFN-γ levels and immunoexpression of iNOS, NF-κB, and TNF-α. Histopathologically, CMN restored DOX-associated cardiac and liver structural alterations. CMN showed anti-oxidative and anti-inflammatory potentials in both the cardiac and hepatic tissues. In addition, cTn1, IFN-γ, and AST could be used as blood-based biomarkers.
Literature
1.
Prša, P., Karademir, B., Biçim, G., Mahmoud, H., Dahan, I., Yalçın, A. S., et al. (2020). The potential use of natural products to negate hepatic, renal and neuronal toxicity induced by cancer therapeutics. Biochemical pharmacology, 173, 113551.PubMed
2.
Chari, R. V. (2008). Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Accounts of chemical research, 41(1), 98–107.PubMed
3.
Fraczkowska, K., Bacia, M., Przybyło, M., Drabik, D., Kaczorowska, A., Rybka, J., et al. (2018). Alterations of biomechanics in cancer and normal cells induced by doxorubicin. Biomedicine & Pharmacotherapy, 97, 1195–1203.
4.
5.
6.
Ibrahim Fouad, G., & Ahmed, K. A. (2021). The protective impact of Berberine against Doxorubicin-induced nephrotoxicity in Rats. Tissue and Cell, 1, 101612.
7.
8.
Magdy, T., Burmeister, B. T., & Burridge, P. W. (2016). Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing? Pharmacology & Therapeutics, 168, 113–125.
9.
Zhang, K. W., Finkelman, B. S., Gulati, G., Narayan, H. K., Upshaw, J., Narayan, V., et al. (2018). Abnormalities in 3-dimensional left ventricular mechanics with anthracycline chemotherapy are associated with systolic and diastolic dysfunction. Journal of the American College of Cardiology, 11, 1059–1068. https://​doi.​org/​10.​1016/​j.​jcmg.​2018.​01.​015CrossRef
10.
11.
Priya, L. B., Baskaran, R., Huang, C. Y., & Padma, V. V. (2017). Neferine ameliorates cardiomyoblast apoptosis induced by doxorubicin: Possible role in modulating NADPH oxidase/ROS-mediated NFκB redox signaling cascade. Scientific reports, 7(1), 1–13.
12.
Songbo, M., Lang, H., Xinyong, C., Bin, X., Ping, Z., & Liang, S. (2019). Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicology letters, 307, 41–48.PubMed
13.
Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Prasad, S. V. N., et al. (2014). Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. The Journal of Clinical Investigation, 124(2), 617–630.PubMedPubMedCentral
14.
Singh, M. K., Mohd, F., Ayaz, A., Ankur, S., & Jyoti, Y. (2012). Protective effect of Lagenaria siceraria against doxorubicin induced cardiotoxicity in wistar rats. International Journal of Drug Development and Research, 4(2), 298–305.
15.
Zhang, Y. W., Shi, J., Li, Y. J., & Wei, L. (2009). Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Archivum Immunologiae et Therapiae Experimentalis, 57(6), 435–445.PubMedPubMedCentral
16.
Chopra, S., & Saxena, R. (2018). Drug-induced liver injury-perspectives from pathology. Current Pharmacology Reports, 4(3), 182–192.
17.
Pedrycz, A., Wieczorski, M., & Czerny, K. (2004). Increased apoptosis in the adult rat liver after a single dose of adriamycin administration. Annales Universitatis Mariae Curie-Sklodowska D, 59(2), 313–318.
18.
Kalender, Y., Yel, M., & Kalender, S. (2005). Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats: The effects of vitamin E and catechin. Toxicology, 209(1), 39–45.PubMed
19.
Dunn, G. P., Ikeda, H., Bruce, A. T., Koebel, C., Uppaluri, R., Bui, J., et al. (2005). Interferon-γ and cancer immunoediting. Immunologic Research, 32(1), 231–245.PubMed
20.
21.
Jorgovanovic, D., Song, M., Wang, L., & Zhang, Y. (2020). Roles of IFN-γ in tumor progression and regression: A review. Biomarker Research., 8(1), 1–16.
22.
Dobrzanski, M. J. (2013). Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Frontiers in Oncology, 3, 63.PubMedPubMedCentral
23.
Mandai, M., Hamanishi, J., Abiko, K., Matsumura, N., Baba, T., & Konishi, I. (2016). Dual faces of IFN-gamma in cancer progression: A role of pd-l1 induction in the determination of pro- and antitumor immunity. Clinical Cancer Research., 22, 2329–2334.PubMed
24.
Mojic, M., Takeda, K., & Hayakawa, Y. (2017). The dark side of IFN-gamma: Its role in promoting cancer immunoevasion. International Journal of Molecular Sciences, 19, 89.PubMedCentral
25.
Choudhari, A. S., Mandave, P. C., Deshpande, M., Ranjekar, P., & Prakash, O. (2020). Phytochemicals in cancer treatment: From preclinical studies to clinical practice. Frontiers in Pharmacology, 10, 1614.PubMedPubMedCentral
26.
Ojha, S., Venkataraman, B., Kurdi, A., Mahgoub, E., Sadek, B., & Rajesh, M. (2016). Plant-derived agents for counteracting cisplatin-induced nephrotoxicity. Oxidative medicine and cellular longevity.‏
27.
Tuorkey, M. J. (2015). Cancer therapy with phytochemicals: Present and future perspectives. Biomedical and Environmental Sciences, 28(11), 808–819.PubMed
28.
Sak, K. (2012). Chemotherapy and dietary phytochemical agents. Chemotherapy research and practice.‏
29.
González-Salazar, A., Molina-Jijón, E., Correa, F., Zarco-Márquez, G., Calderón-Oliver, M., Tapia, E., et al. (2011). Curcumin protects from cardiac reperfusion damage by attenuation of oxidant stress and mitochondrial dysfunction. Cardiovascular Toxicology, 11(4), 357.PubMed
30.
Fan, X., Zhang, C., Liu, D. B., Yan, J., & Liang, H. P. (2013). The clinical applications of curcumin: Current state and the future. Current Pharmaceutical Design, 19(11), 2011–2031.PubMed
31.
Rezaee, R., Momtazi, A. A., Monemi, A., & Sahebkar, A. (2017). Curcumin: A potentially powerful tool to reverse cisplatin-induced toxicity. Pharmacological Research, 117, 218–227.PubMed
32.
Benzer, F., Kandemir, F. M., Ozkaraca, M., Kucukler, S., & Caglayan, C. (2018). Curcumin ameliorates doxorubicin-induced cardiotoxicity by abrogation of inflammation, apoptosis, oxidative DNA damage, and protein oxidation in rats. Journal of Biochemical and Molecular Toxicology, 32(2), e22030.
33.
34.
Ma, Z., Wang, N., He, H., & Tang, X. (2019). Pharmaceutical strategies of improving oral systemic bioavailability of curcumin for clinical application. Journal of Controlled Release., 316, 359–380.PubMed
35.
Chen, K., Pan, H., Yan, Z., Li, Y., Ji, D., Yun, K., et al. (2021). A novel alginate/gelatin sponge combined with curcumin-loaded electrospun fibers for postoperative rapid hemostasis and prevention of tumor recurrence. International Journal of Biological Macromolecules., 182, 1339–1350.PubMed
36.
Paul, S., & Sa, G. (2021). Curcumin as an adjuvant to cancer immunotherapy. Frontiers in Oncology., 11, 675.
37.
Lv, X., Zhu, Y., Deng, Y., Zhang, S., Zhang, Q., Zhao, B., & Li, G. (2020). Glycyrrhizin improved autophagy flux via HMGB1-dependent Akt/mTOR signaling pathway to prevent Doxorubicin-induced cardiotoxicity. Toxicology, 441, 152508.PubMed
38.
Yu, W., Wu, J., Cai, F., Xiang, J., Zha, W., Fan, D., et al. (2012). Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats. PLoS ONE, 7(12), e52013.PubMedPubMedCentral
39.
Reitman, S., & Frankel, S. (1957). In vitro determination of transaminase activity in serum. American Journal of Clinical Pathology, 28(1), 56–63.PubMed
40.
Tietz, N. W., Burtis, C. A., Duncan, P., et al. (1983). A reference method for measurement of alkaline phosphatase activity in human serum. Clinical Chemistry, 29, 751–761.PubMed
41.
Koracevic, D., Koracevic, G., Djordjevic, V., Andrejevic, S., & Cosic, V. (2001). Method for the measurement of antioxidant activity in human fluids. Journal of Clinical Pathology, 54(5), 356–361.PubMedPubMedCentral
42.
Ohkawa, H., Ohishi, N., & Yagi, K. (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry, 95, 351.PubMed
43.
44.
Allain, C. C., Poon, L. S., Chan, C. S., Richmond, W., & Fu, P. C. (1974). Enzymatic determination of total serum cholesterol. Clinical Chemistry, 20(4), 470–475.PubMed
45.
Fassati, P., & Prencipe, L. (1982). Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clinical Chemistry, 28(10), 2077–2080.
46.
Suvarna, S. K., Layton, C., & Bancroft, J. D. (2019). Bancroft’s Theory and Practice of Histological Techniques. Churchill Livingstone Elsevier.
47.
Ahmed, K. A., Korany, R. M. S., El Halawany, H. A., & Ahmed, K. S. (2019). Spirulina platensis alleviates arsenic-induced toxicity in male rats: Biochemical, histopathological and immunohistochemical studies. Adv. Anim. Vet. Sci., 7(8), 701–710.
48.
Martín-Burriel, I., et al. (2004). Histopathological and molecular changes during apoptosis produced by 7H-dibenzo [c, g]-carbazole in mouse liver. Toxicologic Pathology, 32(2), 202–211.PubMed
49.
Yu, J., Wang, C., Kong, Q., Wu, X., Lu, J. J., & Chen, X. (2018). Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products. Phytomedicine, 40, 125–139.PubMed
50.
Gonzalez, Y., Pokrzywinski, K. L., Rosen, E. T., Mog, S., Aryal, B., Chehab, L. M., Vijay, V., Moland, C. L., Desai, V. G., Dickey, J. S., et al. (2015). Reproductive hormone levels and differential mitochondria-related oxidative gene expression as potential mechanisms for gender differences in cardiosensitivity to doxorubicin in tumor-bearing spontaneously hypertensive rats. Cancer Chemotherapy and Pharmacology, 76(3), 447–459.PubMed
51.
O’brien, P. J., Smith, D. E. C., Knechtel, T. J., Marchak, M. A., Pruimboom-Brees, I., Brees, D. J., Spratt, D. P., Archer, F. J., Butler, P., Potter, A. N., & Provost, J. P. (2006). Cardiac troponin I is a sensitive, specific biomarker of cardiac injury in laboratory animals. Laboratory Animals, 40(2), 153–171.PubMed
52.
Ahmed, L. A., Abdou, F. Y., El Fiky, A. A., Shaaban, E. A., & Ain-Shoka, A. A. (2021). Bradykinin-potentiating activity of a gamma-irradiated bioactive fraction isolated from scorpion (Leiurus quinquestriatus) venom in rats with doxorubicin-induced acute cardiotoxicity: Favorable modulation of oxidative stress and inflammatory, fibrogenic and apoptotic pathways. Cardiovascular Toxicology, 21(2), 127–141.PubMed
53.
Botelho, A. F. M., Lempek, M. R., Branco, S. E. M., Nogueira, M. M., de Almeida, M. E., Costa, A. G., et al. (2019). Coenzyme Q10 cardioprotective effects against doxorubicin-induced cardiotoxicity in Wistar Rat. Cardiovascular Toxicology, 1, 1–13.
54.
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003). Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer Interdisciplinary International Journal of the American Cancer Society, 97(11), 2869–2879.
55.
Goudarzi, M., Fatemi, I., Siahpoosh, A., Sezavar, S. H., Mansouri, E., & Mehrzadi, S. (2018). Protective effect of ellagic acid against sodium arsenite-induced cardio-and hematotoxicity in rats. Cardiovascular Toxicology, 18(4), 337–345.PubMed
56.
Haybar, H., Goudarzi, M., Mehrzadi, S., Aminzadeh, A., Khodayar, M. J., Kalantar, M., & Fatemi, I. (2019). Effect of gemfibrozil on cardiotoxicity induced by doxorubicin in male experimental rats. Biomedicine & Pharmacotherapy, 109, 530–535.
57.
Chen, Y., Jiang, W., Liu, X., Du, Y., Liu, L., Ordovas, J. M., et al. (2020). Curcumin supplementation improves heat-stress-induced cardiac injury of mice: Physiological and molecular mechanisms. The Journal of Nutritional Biochemistry, 78, 108331.PubMed
58.
Damodar, G., Smitha, T., Gopinath, S., Vijayakumar, S., & Rao, Y. (2014). An evaluation of hepatotoxicity in breast cancer patients receiving injection doxorubicin. Annals of Medical and Health Sciences Research, 4, 74–79.PubMedPubMedCentral
59.
Mohammed, H. S., Hosny, E. N., Khadrawy, Y. A., Magdy, M., Attia, Y. S., Sayed, O. A., & AbdElaal, M. (2020). Protective effect of curcumin nanoparticles against cardiotoxicity induced by doxorubicin in rat. Biochimica et Biophysica Acta Molecular Basis of Disease, 1866(5), 165665.PubMed
60.
Mete, R., Oran, M., Topcu, B., Oznur, M., Seber, E. S., Gedikbasi, A., & Yetisyigit, T. (2016). Protective effects of onion (Allium cepa) extract against doxorubicin-induced hepatotoxicity in rats. Toxicology and Industrial Health, 32(3), 551–557.PubMed
61.
Omobowale, T. O., Oyagbemi, A. A., Ajufo, U. E., Adejumobi, O. A., Ola-Davies, O. E., Adedapo, A. A., & Yakubu, M. A. (2018). Ameliorative effect of gallic acid in doxorubicin-induced hepatotoxicity in Wistar rats through antioxidant defense system. Journal of Dietary Supplements, 15(2), 183–196.PubMed
62.
Wang, Y., Mei, X., Yuan, J., Lu, W., Li, B., & Xu, D. (2015). Taurine zinc solid dispersions attenuate doxorubicin-induced hepatotoxicity and cardiotoxicity in rats. Toxicology and Applied Pharmacology, 289(1), 1–11.PubMed
63.
64.
Koenig, G., & Seneff, S. (2015). Gamma-glutamyltransferase: A predictive biomarker of cellular antioxidant inadequacy and disease risk. Disease Markers.‏
65.
Mohamed, R. H., Karam, R. A., & Amer, M. G. (2011). Epicatechin attenuates doxorubicin-induced brain toxicity: Critical role of TNF-α, iNOS and NF-κB. Brain Research Bulletin, 86(1–2), 22–28.PubMed
66.
El-Moselhy, M. A., & El-Sheikh, A. A. (2014). Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity. Biomedicine & Pharmacotherapy, 68, 101–110.
67.
Chen, X., Zhang, Y., Zhu, Z., Liu, H., Guo, H., Xiong, C., et al. (2016). Protective effect of berberine on doxorubicin induced acute hepatorenal toxicity in rats. Molecular Medicine Reports, 13(5), 3953–3960.PubMed
68.
Kelleni, M. T., Amin, E. F., & Abdelrahman, A. M. (2015). Effect of metformin and sitagliptin on doxorubicin-induced cardiotoxicity in rats: impact of oxidative stress, inflammation, and apoptosis. Journal of Toxicology, 2015, 1–8.
69.
LeBaron, T. W., Kura, B., Kalocayova, B., Tribulova, N., & Slezak, J. (2019). A new approach for the prevention and treatment of cardiovascular disorders: Molecular hydrogen significantly reduces the effects of oxidative stress. Molecules, 24(11), 2076.PubMedCentral
70.
Sun, J., Sun, G., Cui, X., Meng, X., Qin, M., & Sun, X. (2016). Myricitrin protects against doxorubicin-induced cardiotoxicity by counteracting oxidative stress and inhibiting mitochondrial apoptosis via ERK/P53 pathway. Evidence-Based Complementary and Alternative Medicine, 2016, 1–5.
71.
Durdagi, G., Pehlivan, D. Y., Oyar, E. O., Bahceci, S. A., & Ozbek, M. (2021). Effects of melatonin and adrenomedullin in reducing the cardiotoxic effects of doxorubicin in rats. Cardiovascular Toxicology, 21(5), 354–364.PubMed
72.
Zare, M. F. R., Rakhshan, K., Aboutaleb, N., Nikbakht, F., Naderi, N., Bakhshesh, M., & Azizi, Y. (2019). Apigenin attenuates doxorubicin induced cardiotoxicity via reducing oxidative stress and apoptosis in male rats. Life Sciences, 232, 116623.PubMed
73.
Shaker, R. A., Abboud, S. H., Assad, H. C., & Hadi, N. (2018). Enoxaparin attenuates doxorubicin induced cardiotoxicity in rats via interfering with oxidative stress, inflammation and apoptosis. BMC Pharmacology and Toxicology, 19(1), 1–10.
74.
Tan, B. L., & Norhaizan, M. E. (2019). Curcumin combination chemotherapy: The implication and efficacy in cancer. Molecules, 24(14), 2527.PubMedCentral
75.
Ma, Y., Yang, L., Ma, J., Lu, L., Wang, X., Ren, J., & Yang, J. (2017). Rutin attenuates doxorubicin-induced cardiotoxicity via regulating autophagy and apoptosis. Biochimica et Biophysica Acta, 1863(8), 1904–1911.PubMed
76.
Rahman, I. (2002). Oxidative stress, transcription factors and chromatin remodelling in lung inflammation. Biochemical Pharmacology, 64(5–6), 935–942.PubMed
77.
Aziz, M. M., Abd El Fattah, M. A., Ahmed, K. A., & Sayed, H. M. (2020). Protective effects of olmesartan and l-carnitine on doxorubicin-induced cardiotoxicity in rats. Canadian Journal of Physiology and Pharmacology, 98(4), 183–193.PubMed
78.
79.
Ni, C., Ma, P., Wang, R., Lou, X., Liu, X., Qin, Y., et al. (2019). Doxorubicin-induced cardiotoxicity involves IFNγ-mediated metabolic reprogramming in cardiomyocytes. The Journal of Pathology, 247(3), 320–332.PubMed
80.
Levick, S. P., & Goldspink, P. H. (2014). Could interferon-gamma be a therapeutic target for treating heart failure? Heart Failure Reviews, 19(2), 227–236.PubMedPubMedCentral
81.
Sadek, K. M., Mahmoud, S. F., Zeweil, M. F., & Abouzed, T. K. (2021). Proanthocyanidin alleviates doxorubicin-induced cardiac injury by inhibiting NF-kB pathway and modulating oxidative stress, cell cycle, and fibrogenesis. Journal of Biochemical and Molecular Toxicology, 35(4), e22716.PubMed
82.
Cosper, P. F., Harvey, P. A., & Leinwand, L. A. (2012). Interferon-gamma causes cardiac myocyte atrophy via selective degradation of myosin heavy chain in a model of chronic myocarditis. American Journal of Pathology., 181, 2038–2046.
83.
Sauter, K. A., Wood, L. J., Wong, J., Iordanov, M., & Magun, B. E. (2011). Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome: Progress at a snail’s pace. Cancer Biology & Therapy, 11(12), 1008–1016.
84.
Ma, P., Qin, Y., Cao, H., Erben, U., Ni, C., & Qin, Z. (2020). Temporary blockade of interferon-γ ameliorates doxorubicin-induced cardiotoxicity without influencing the anti-tumor effect. Biomedicine & Pharmacotherapy, 130, 110587.
85.
Qin, Z., Schwartzkopff, J., Pradera, F., Kammertœns, T., Seliger, B., Pircher, H., & Blankenstein, T. (2003). A critical requirement of interferon γ-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Research, 63(14), 4095–4100.PubMed
86.
Todorović-Raković, N. (2021). The role of cytokines in the evolution of cancer: IFN-γ paradigm. Cytokine, 1, 155442.
87.
Aktaş, I., Özmen, Ö., Tutun, H., Yalçın, A., & Türk, A. (2020). Artemisinin attenuates doxorubicin induced cardiotoxicity and hepatotoxicity in rats. Biotechnic & Histochemistry, 95(2), 121–128.
88.
Akama, K. T., & Van Eldik, L. J. (2000). β-Amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1β-and tumor necrosis factor-α (TNFα)-dependent, and involves a TNFα receptor-associated factor-and NFκB-inducing kinase-dependent signaling mechanism. Journal of Biological Chemistry, 275(11), 7918–7924.
89.
Elsharkawy, A. M., & Mann, D. A. (2007). Nuclear factor-κB and the hepatic inflammation-fibrosis-cancer axis. Hepatology, 46(2), 590–597.PubMed
90.
Aggarwal, B. B. (2003). Signalling pathways of the TNF superfamily: A double-edged sword. Nature Reviews Immunology, 3(9), 745–756.PubMed
91.
Ahmad, S., Abbas, M., Ullah, M. F., Aziz, M. H., Beylerli, O., Alam, M. A., et al. (2021). Long non-coding RNAs regulated NF-κB signaling in cancer metastasis: Micromanaging by not so small non-coding RNAs. Academic Press.
92.
Lo, S. Z., Steer, J. H., & Joyce, D. A. (2011). TNF-α renders macrophages resistant to a range of cancer chemotherapeutic agents through NF-κB-mediated antagonism of apoptosis signaling. Cancer Letters, 307(1), 80–92.PubMed
93.
Chen, Y., Tang, Y., Zhang, Y. C., Huang, X. H., Xie, Y. Q., & Xiang, Y. (2015). A metabolomic study of rats with doxorubicin-induced cardiomyopathy and Shengmai injection treatment. PLoS ONE, 10(5), e0125209.PubMedPubMedCentral
94.
Mohebbati, R., Khajavi Rad, A., Naser Shafei, M., Soukhtanloo, M., Hosseinian, S., Beheshti, F., & Reza Khazdair, M. (2015). The effects of vitamin C on adriamycin-induced hypercholesterolemia in rat. Current Nutrition & Food Science, 11(4), 309–314.
95.
Lee, B. H., Taylor, M. G., Robinet, P., Smith, J. D., Schweitzer, J., Sehayek, E., et al. (2013). Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. Cancer Research, 73, 1211–1218.PubMed
96.
Liu, Z., Huang, P., Law, S., Tian, H., Leung, W., & Xu, C. (2018). Preventive effect of curcumin against chemotherapy-induced side-effects. Frontiers in Pharmacology, 9, 1374.PubMedPubMedCentral
Metadata
Title
Curcumin Ameliorates Doxorubicin-Induced Cardiotoxicity and Hepatotoxicity Via Suppressing Oxidative Stress and Modulating iNOS, NF-κB, and TNF-α in Rats
Authors
Ghadha Ibrahim Fouad
Kawkab A. Ahmed
Publication date
01-02-2022
Publisher
Springer US
Keyword
Interferon
Published in
Cardiovascular Toxicology / Issue 2/2022
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI
https://doi.org/10.1007/s12012-021-09710-w

Other articles of this Issue 2/2022

Cardiovascular Toxicology 2/2022 Go to the issue

OriginalPaper

In Vivo Cardiotoxic Potential of Micrurus frontalis Venom

OriginalPaper

Association of Matrix Metalloproteinase-2 (MMP-2) and MMP-9 Promoter Polymorphisms, Their Serum Levels, and Activities with Coronary Artery Calcification (CAC) in an Iranian Population

OriginalPaper

Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy

OriginalPaper

MiR-7a-5p Attenuates Hypoxia/Reoxygenation-Induced Cardiomyocyte Apoptosis by Targeting VDAC1

OriginalPaper

Metoprolol Protects Against Arginine Vasopressin-Induced Cellular Senescence in H9C2 Cardiomyocytes by Regulating the Sirt1/p53/p21 Axis

OriginalPaper

Yohimbine Directly Induces Cardiotoxicity on Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits